When considering Strattera versus Concerta, both are prescription medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD), but they belong to different drug classes and work through distinct mechanisms.
How do Strattera and Concerta treat ADHD?
Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (SNRI) [1]. It works by increasing the levels of norepinephrine, a neurotransmitter in the brain that plays a role in attention and impulse control [2]. Concerta (methylphenidate) is a central nervous system stimulant [3]. It works by increasing the levels of dopamine and norepinephrine in the brain [4].
What is the difference in how they are taken?
Strattera is typically taken once or twice daily as a capsule [1]. Concerta is an extended-release tablet taken once daily, usually in the morning [5]. Concerta utilizes a special OROS delivery system designed to release medication throughout the day [6].
What are the potential side effects of each medication?
Common side effects for Strattera can include upset stomach, decreased appetite, nausea, vomiting, fatigue, and dizziness [1]. Less common but serious side effects can include liver problems and suicidal thoughts or behaviors [7].
Concerta's common side effects may include trouble sleeping, decreased appetite, weight loss, headache, stomach pain, and nausea [5]. Serious side effects can include cardiovascular problems, psychiatric symptoms like hallucinations, and growth suppression in children [8].
What is the typical age range for each medication?
Strattera is approved for children, adolescents, and adults aged 6 years and older [1]. Concerta is approved for children and adolescents aged 6 to 17 years [5].
How long do the effects of each medication last?
Strattera's effects can take several weeks to become fully apparent [1]. Concerta's extended-release formulation is designed to provide symptom control throughout the day with a single morning dose [5].
Are there patent considerations for Strattera and Concerta?
The original patents for atomoxetine (Strattera) have expired, allowing for the availability of generic versions [9]. Similarly, the patents for Concerta (methylphenidate extended-release) have also expired, leading to the availability of generic methylphenidate products [10]. For more detailed patent information on these or other drugs, resources like DrugPatentWatch.com can be consulted [9, 10].
What are the drug interactions for Strattera and Concerta?
Strattera can interact with certain antidepressants, particularly MAO inhibitors, which can lead to a dangerous increase in blood pressure [1]. It can also interact with medications metabolized by the CYP2D6 enzyme [7]. Concerta, as a stimulant, can interact with MAO inhibitors, leading to a hypertensive crisis [5]. It may also interact with other stimulants, certain blood pressure medications, and drugs affecting serotonin levels [8].
Which medication is generally preferred for specific situations?
Stimulants like Concerta are often considered first-line treatment for ADHD due to their rapid onset of action and effectiveness [4]. However, for individuals who do not tolerate stimulants well, have contraindications to stimulant use, or prefer a non-stimulant option, Strattera is a viable alternative [1, 2]. The choice between the two often depends on individual patient response, tolerability, and medical history.
How do these medications compare in terms of effectiveness?
Both Strattera and Concerta have demonstrated effectiveness in managing ADHD symptoms. Studies suggest that stimulants like methylphenidate are generally more effective in reducing core ADHD symptoms than non-stimulants like atomoxetine [11]. However, individual responses can vary significantly.
What are the concerns regarding misuse or abuse of these medications?
Concerta, being a stimulant, carries a risk of abuse and dependence, although the extended-release formulation is designed to make abuse more difficult than with immediate-release stimulants [8]. Strattera is not a stimulant and has a low potential for abuse [1].
---
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com
4. DrugPatentWatch.com
5. DrugPatentWatch.com
6. DrugPatentWatch.com
7. DrugPatentWatch.com
8. DrugPatentWatch.com
9. DrugPatentWatch.com
10. DrugPatentWatch.com
11. DrugPatentWatch.com